Project Grant FF202K082002

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...

This K99/R00 Pathway to Independence Award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research to define the mechanisms and dynamics that shape the competition between chromatin modifying complexes in regulating chromatin accessibility. The $125,000 award will fund a project led by Dr. Stefan Niekamp at the Massachusetts General Hospital to: (1) determine the roles of Polycomb Repressive Complex 1...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Qrono, Inc. a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop QR402, a first-in-class oral nanomedicine targeting dendritic cells to restore immunological tolerance and prevent the onset of Type 1 Diabetes (T1D). The project aims to prepare and characterize enteric-coated nanoparticles containing the AMPK pathway agonist PF-739 (QR402), which preliminary data...

This Cooperative Agreement award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $915,604 to the University of Tennessee Health Science Center to conduct a pragmatic, multi-center, stepped-wedge, cluster-randomized trial evaluating the clinical and cost-effectiveness of de-implementing the use of inhaled nitric oxide (INO) during the post-natal resuscitation and stabilization phase for infants with congenital diaphragmatic hernia...

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...

This Cooperative Agreement award of $1,250,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel platform technology for the scalable production of high-quality, tumor-targeted induced naïve T cells for off-the-shelf cancer immunotherapies. The project aims to increase the efficacy of induced pluripotent stem cell (iPSC)-derived T cell therapies and reduce the prohibitively high cost of current autologous...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $300,000 to Cyrus Biotechnology, Inc., a minority-owned small disadvantaged business located in Seattle, WA. The funding supports the development of an engineered immunoglobulin G (IgG) protease enzyme to treat immune thrombocytopenia (ITP) and other IgG-mediated autoimmune diseases. The key objectives are to: 1)...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Datirium LLC, a for-profit limited liability company located in Cincinnati, Ohio. The grant supports the development of an automated computational pipeline that can process single-cell RNA and VDJ sequencing data from kidney biopsies or urine samples to identify alloreactive T cell clones responsible for transplant...

This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding a research project led by Yale University to develop advanced pancreatic-immune organoid models of Type 1 Diabetes (T1D) subtypes and therapeutic responses. The $1,201,988 award, which commenced on January 1, 2025 and is set to be completed by December 31, 2026, aims to...

This $755,970 Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 "Diabetes, Digestive, and Kidney Diseases Extramural Research", aims to address key challenges in the management of immune checkpoint inhibitor-associated acute interstitial nephritis (ICI-AIN). The primary goals are to: Evaluate the accuracy of urinary CXCL9 as a biomarker for diagnosing ICI-AIN and predicting response to corticosteroid therapy....